AI-generated analysis. Always verify with the original filing.
Cardiff Oncology, Inc. entered into separation agreements with former CEO Dr. Mark Erlander and CFO James Levine effective March 27, 2026, providing severance payments and benefits following their January 2026 departures.
Event Type
Disclosure
Mandatory
Variant
8-K
Entry into a Material Definitive Agreement. Previously on January 26, 2026, Cardiff Oncology, Inc. (the “Company”) disclosed that Dr. Mark Erlander, CEO and Jam
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. The information set forth above under Item 1.01 is incor
Dr. Mark Erlander
Effective: 2026-03-27
Strategic review
James Levine
Effective: 2026-03-27
Strategic review
Material Agreement